Roche signs backloaded $2B allosteric small-molecule deal with Atavistik Bio for CVRM diseases
核心洞察
Roche will pay Atavistik Bio (搜索) $70 million upfront and up to $1.9 billion in research, development and commercial milestones, plus royalties on approved drugs.
The partnership uses Atavistik's metabolite-protein screening platform to find cryptic binding pockets on proteins that conventional approaches struggle to reach.
Atavistik leads discovery and research while Roche takes over preclinical work, human testing, regulatory filings and commercialization in cardiovascular, renal and metabolic diseases.
Roche has signed a drug-discovery agreement with Atavistik Bio (搜索) potentially worth nearly $2 billion to develop oral allosteric small molecules for cardiovascular, renal and metabolic (CVRM) diseases. The Cambridge, Massachusetts-based biotech announced the deal on Sept. 24, with Roche paying $70 million upfront and up to $1.9 billion in research, development and commercial milestone payments, plus royalties on sales of approved drugs.
The partnership covers multiple drug targets and will use Atavistik's metabolite-protein screening (AMPS) platform to identify novel functional binding pockets on disease-causing proteins. According to the companies, this approach could allow drugs to be developed against targets that conventional methods have struggled to reach.
Allosteric binding as the scientific premise
Unlike many traditional drugs that bind to a protein's main active site, Atavistik's approach targets other sites that regulate how the protein works. The company describes its platform as a way to uncover cryptic, biologically relevant binding pockets, which could allow for more selective treatments with fewer unintended effects.
Under the collaboration structure, Atavistik will lead early discovery and research activities. Roche will then handle further preclinical work, human testing, regulatory filings and commercialization. The companies did not disclose the number of targets covered by the partnership or provide development timelines.
"This collaboration reflects the strength and broad applicability of our platform across therapeutic areas, further validating our approach to allosteric drug discovery," Atavistik CEO Bryan Stuart said in the release. "We are excited to extend the application of our platform into CVRM diseases by leveraging Roche's deep expertise in the field, while we remain focused internally on advancing a robust pipeline of potentially best-in-class therapies for patients with rare hematologic diseases."
Atavistik's internal pipeline stays in rare blood disorders
Atavistik will continue developing its own treatments for rare blood disorders, including hereditary hemorrhagic telangiectasia (搜索), a severe, multi-organ disease that causes malformed blood vessels. The company's lead asset is ATV-1601, an oral allosteric inhibitor of AKT1 (搜索) that is undergoing a phase 1/2 study in that indication. Atavistik also has allosteric JAK2 (搜索) selective inhibitors in preclinical development for myeloproliferative neoplasms (搜索).
Those programs have been funded by $160 million in series B financing raised over the past year from investors including RA Capital Management and Regeneron Ventures.
Roche's expanding CVRM footprint
CVRM sits outside Roche's historical core focus, which has predominantly been oncology with drugs such as Avastin and Herceptin and, more recently, rare disease, including the approval of its spinal muscular atrophy (搜索) treatment Evrysdi. The company has been expanding in the area, including by shifting this work into a dedicated research campus in Boston.
Roche has also increased its dealmaking in CVRM in recent years. That includes a partnership with Alnylam on the RNAi hypertension therapeutic zilebesiran, $3.5 billion for 89bio and its fatty liver disease drug, and the $2.7 billion takeover of Carmot Therapeutics (搜索) to stock its obesity and diabetes pipeline.
"Treating CVRM diseases remains a core strategic priority for Roche," Boris Zaïtra, head of corporate business development at the pharma, said in the release. "By pairing Atavistik Bio (搜索)'s novel approach to discovering allosteric small molecules with our expertise in disease biology and drug development, we aim to translate complex science into transformative, oral small-molecule therapeutics for patients who need them most."